Inside Nephrology: A Weekly Review
Nefrologia
Advances in Nephrology: Combination Therapies and Glomerular Disease Outcomes
This week we discuss combination therapies for CKD and diabetes, examining finerenone-empagliflozin synergy and blood pressure effects. We also explore new insights into C3 glomerulopathy and IC-MPGN outcomes post-transplantation, plus pediatric progression patterns.
Bibliography
1. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
2. Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.
Authors: Ruiz-Cabello JE, Yandian F, Torres IB, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42462202
DOI: 10.2215/CJN.0000001117
3. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.
Authors: McGill JB, Green JB, Heerspink HJL, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42297748
DOI: 10.1111/dom.70949
4. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Journal of the American Society of Nephrology : JASN, 2026 Sep 1
PMID: 41905767
DOI: 10.1681/ASN.0000001071
5. Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.
Authors: Dixon BP, Laskin BL, Goodwin Davies AJ, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42329702
DOI: 10.2215/CJN.0000001118
6. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
7. Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.
Authors: Iriyama N, Takahashi N, Fujimaki K, et al.
Journal: British journal of haematology, 2026 Sep
PMID: 42422985
DOI: 10.1111/bjh.70678
8. A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes.
Authors: Elmorsy YH, Elshal AM, El-Nahas AR, et al.
Journal: Prostate cancer and prostatic diseases, 2026 Sep
PMID: 41198920
DOI: 10.1038/s41391-025-01040-0
9. A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.
Authors: Gugliandolo S, Morciano C, Guarneri A, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42337820
DOI: 10.1111/dom.71026
10. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
Authors: Takeuchi T, van Vollenhoven R, Ueki Y, et al.
Journal: Modern rheumatology, 2026 Aug 31
PMID: 41967478
DOI: 10.1093/mr/roag031
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
2. Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.
Authors: Ruiz-Cabello JE, Yandian F, Torres IB, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42462202
DOI: 10.2215/CJN.0000001117
3. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.
Authors: McGill JB, Green JB, Heerspink HJL, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42297748
DOI: 10.1111/dom.70949
4. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Journal of the American Society of Nephrology : JASN, 2026 Sep 1
PMID: 41905767
DOI: 10.1681/ASN.0000001071
5. Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.
Authors: Dixon BP, Laskin BL, Goodwin Davies AJ, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42329702
DOI: 10.2215/CJN.0000001118
6. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
7. Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.
Authors: Iriyama N, Takahashi N, Fujimaki K, et al.
Journal: British journal of haematology, 2026 Sep
PMID: 42422985
DOI: 10.1111/bjh.70678
8. A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes.
Authors: Elmorsy YH, Elshal AM, El-Nahas AR, et al.
Journal: Prostate cancer and prostatic diseases, 2026 Sep
PMID: 41198920
DOI: 10.1038/s41391-025-01040-0
9. A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.
Authors: Gugliandolo S, Morciano C, Guarneri A, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42337820
DOI: 10.1111/dom.71026
10. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
Authors: Takeuchi T, van Vollenhoven R, Ueki Y, et al.
Journal: Modern rheumatology, 2026 Aug 31
PMID: 41967478
DOI: 10.1093/mr/roag031
